Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz394.060
Abstract: Abstract Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with stage I-III endometrial cancer with high-risk features (HREC). Since the TCGA defined 4… read more here.
Keywords: board directors; portec trial; officer board;